Aldagen, Inc, a wholly-owned subsidiary of Cytomedix, Inc (BB:CMXI), specializes in developing proprietary regenerative cell therapies in the vascular area. The company focuses on isolating a specific population of stem cells from a patient’s own bone marrow, utilizing their proprietary technology. These cells, which typically represent less than 1% of all cells in bone marrow, have shown promising potential in promoting the regeneration of various types of cells and tissues, including the growth of new blood vessels (angiogenesis). Aldagen's product candidates include ALD-301 for critical limb ischemia, ALD-201 for ischemic heart failure, and ALD-401 for ischemic stroke. Founded in 2001, the company operates within the Biotechnology, Health Care, and Health and Wellness sectors. Their last recorded investment was a $585.00K debt financing on 13th January 2012, with no specified investors or headquarters.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $585.00K | - | 13 Jan 2012 | |
| Debt Financing | $1.08M | - | 23 Jun 2011 | |
| Debt Financing | $7.29M | - | 22 Oct 2009 | |
| Series D | $18.40M | 4 |
|
23 Apr 2008 |
| Series C | $9.00M | 4 |
|
01 Sep 2007 |
No recent news or press coverage available for Aldagen, Inc.
We care about your data, and we'd love to use cookies make your experience better.
-logo.jpg){kind=logo}